regulatory capture
Raghuram Rajan: Populist Nationalism Is “the First Step Toward Crony Capitalism”
The former governor of the Reserve Bank of India discussed the “concentrated and devastating” impact that technology and trade had on blue-collar communities, the anger...
Bribery, Cooperation, and the Evolution of Prosocial Institutions
How the science of cooperation and cultural evolution will give us new tools in combating corruption.
There is nothing natural((Putting aside what it means for...
The Berlusconi Voter, Taken Seriously: a Little Exercise in Historical Comprehension
The Berlusconi phenomenon in Italy both anticipated and exhibits features that epitomize the plight of Western politics.
This is the third installment of ProMarket’s new article...
Eliot Spitzer: The Democratic Party Has Become the Party of the Status Quo
Former New York governor Eliot Spitzer talks about antitrust, digital platforms, economic concentration, and regulatory capture. Part 2 of 2.
In the first part of...
The Big Picture: Clientelism, Plutocracy, and Democratization
Why is the electoral process not enough to rid nations of pathological political distortions such as cronyism and corruption?
This is the second installment of ProMarket’s...
Eliot Spitzer: The U.S. Never Had the Will and the Ability to Hold the Most Powerful to Account
In a special interview with ProMarket, former New York governor Eliot Spitzer talks about financial regulation, regulatory capture, and antitrust. Part 1 of 2.
Clear rules and...
How Biology Explains Back-Scratching Between Wall Street and Government
The revolving door of government and business explained in the lab.
The systemic financial risk-taking in the lead-up to the financial crisis was a product...
Where Friedman Was Wrong
A new paper by Oliver Hart and Luigi Zingales argues that a company’s objective should be the maximization of shareholders’ welfare, not value.
In 1970,...
"The Pharmaceutical Industry Has a Large Amount of Control Over the Field of Oncology"
In the second part of our two-part interview with Daniel Goldstein, MD, an oncologist who studies the influence of business interests on healthcare, we talk...
When Medical Experiments Serve the Business Needs of Pharmaceutical Firms Instead of Science
The first part of a two-part interview with Daniel Goldstein, MD, an oncologist who also studies the influence of business interests on healthcare—from treating patients...
